Araki, Yoshinori
Kawaguchi, Azusa
Sakakibara, Nana
Nagaoka, Yoshinobu
Yamamura, Tomohiko
Horinouchi, Tomoko
Nagano, China
Morisada, Naoya
Iijima, Kazumoto
Nozu, Kandai http://orcid.org/0000-0002-0290-3137
Funding for this research was provided by:
Ministry of Education, Culture, Sports, Science and Technology of Japan (16K19642)
Ministry of Education, Culture, Sports, Science and Technology of Japan (17H04189, 19K08726)
Japan Agency for Medical Research and Development (19ek0109231h0003)
Article History
Received: 14 May 2020
Accepted: 17 June 2020
First Online: 26 June 2020
Compliance with ethical standards
:
: This study was supported by the Grants-in-Aid for Scientific Research (KAKENHI) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (subject ID: 16K19642 to Tomohiko Yamamura and 17H04189 to Kazumoto Iijima, and 19K08726 to Kandai Nozu) and by the Japan Agency for Medical Research and Development (AMED) (Grant number JP19ek0109231h0003 to Kazumoto Iijima and Kandai Nozu).Kandai Nozu and Kazumoto Iijima have filed a patent application on the development of antisense nucleotides for exon skipping therapy in Alport syndrome.Kazumoto Iijima has received grant support from Daiichi Sankyo Co., Ltd.; consulting fees from Kyowa Kirin Co., Ltd., and Boehringer Ingelheim; and lecture fees from Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company, Integrated Development Associates, and Novartis Pharmaceuticals Corporation.Kandai Nozu has received consulting fees from Kyowa Kirin Co., Ltd.; and lecture fees from Kyowa Kirin Co., Ltd., Novartis Pharmaceuticals Corporation, and Chugai Pharmaceutical Co., Ltd.
: No information identifying the individual patient is published, and personal information is protected. The patient, his parents, and his grandmother provided informed consent for the publication of this case report.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee at which the studies were conducted (IRB approval number 301) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: This article does not describe any studies with human participants or animals performed by any of the authors.